The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV
TofCoMS
1 other identifier
observational
230
1 country
1
Brief Summary
Retrospective observational cohort study. ToFCoMS: two years of follow-up of COVID-19 in MS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2022
CompletedFirst Submitted
Initial submission to the registry
June 2, 2022
CompletedFirst Posted
Study publicly available on registry
June 3, 2022
CompletedJune 8, 2022
June 1, 2022
3 months
June 2, 2022
June 3, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
The investigators hereby aim to answer the question whether COVID-19 affects the progression of clinical disability in MS
The difference between the values measured at T-2 and T-1 (i.e., before COVID-19) will be compared, after adjustment for the time interval, with the difference between the respective values measured at T-1 and T1 (i.e., after COVID-19) for T25WT, 9HPT and SDMT. The investigators hereby aim to answer the question whether COVID-19 affects the progression of clinical disability in MS. Its effect on SDMT evolution has been defined as the primary endpoint of our study.
2 years
Secondary Outcomes (1)
vaccination status and progression MS
2 years
Eligibility Criteria
MS patients with Covid 19 infection
You may qualify if:
- diagnosis of Multiple Sclerosis Covid 19 infection with PCR test
You may not qualify if:
- other diagnosis than Multiple Sclerosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Marie D'hooghelead
Study Sites (1)
Nationaal MS center
Melsbroek, Vlaams Brabant, 1820, Belgium
Related Publications (1)
Peeters G, Van Remoortel A, Nagels G, Van Schependom J, D'haeseleer M. Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 17;10(3):e200089. doi: 10.1212/NXI.0000000000200089. Print 2023 May.
PMID: 36807080DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- neuroloog
Study Record Dates
First Submitted
June 2, 2022
First Posted
June 3, 2022
Study Start
March 1, 2022
Primary Completion
June 1, 2022
Study Completion
June 1, 2022
Last Updated
June 8, 2022
Record last verified: 2022-06
Data Sharing
- IPD Sharing
- Will not share
no IPD